23129-Prostate Cancer-NA-1270

Prostate Cancer

Randomized Study of ONC-392 plus Lutetium Lu 177 Vipivotide Tetraxetanin Patients with Metastatic Castration-Resistant Prostate Cancer (mCRPC)who Progressed on Androgen Receptor (AR) Pathway Inhibition (PRESERVE-006)

  • Details

ClinicalTrials.gov ID: NCT05682443
Diagnosis Type: NA
USOR Number:

  • Address


,
P:

Search by practice name, trial titles, indicators and specific disease types.